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Abstract Obesity affects multiple points along the breast
cancer control continuum from prevention to screening and
treatment, often in opposing directions. Obesity is also
more prevalent in Blacks than Whites at most ages so it
might contribute to observed racial disparities in mortality.
We use two established simulation models from the Cancer
Intervention and Surveillance Modeling Network (CIS-
NET) to evaluate the impact of obesity on race-specific
breast cancer outcomes. The models use common national
data to inform parameters for the multiple US birth cohorts
of Black and White women, including age- and race-spe-
cific incidence, competing mortality, mammography char-
acteristics, and treatment effectiveness. Parameters are
modified by obesity (BMI of C30 kg/m2) in conjunction
with its age-, race-, cohort- and time-period-specific prev-
alence. We measure age-standardized breast cancer inci-
dence and mortality and cases and deaths attributable to
obesity. Obesity is more prevalent among Blacks than
Whites until age 74; after age 74 it is more prevalent in
Whites. The models estimate that the fraction of the US
breast cancer cases attributable to obesity is 3.9–4.5 %
(range across models) for Whites and 2.5–3.6 % for
Blacks. Given the protective effects of obesity on risk
among women\50 years, elimination of obesity in this age
group could increase cases for both the races, but decrease
cases for women C50 years. Overall, obesity accounts for
4.4–9.2 % and 3.1–8.4 % of the total number of breast
cancer deaths in Whites and Blacks, respectively, across
models. However, variations in obesity prevalence have no
net effect on race disparities in breast cancer mortality
because of the opposing effects of age on risk and patterns
of age- and race-specific prevalence. Despite its modest
impact on breast cancer control and race disparities,
obesity remains one of the few known modifiable risks for
cancer and other diseases, underlining its relevance as a
public health target.
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Introduction
The burden of breast cancer has been decreasing over time
[1, 2], but mortality gaps between Black and White women
have been persistent [3]. The higher mortality rate for
Black women is particularly striking now, given virtually
equivalent screening rates and lower incidence than White
women [4, 5]. Racial differences in breast cancer outcome
are cast on a backdrop of an obesity epidemic that dis-
proportionately affects Black women. Currently, more than
50 % of Black women are obese (defined as a BMI of
C30 kg/m2), compared to 32.0 % of White women [6, 7]
but there are exceptions to this overall trend, with Whites
having higher rates of obesity after age 74 [6–8].
Y. Chang  A. M. Near  L. Adams-Campbell  D. Levy 
J. S. Mandelblatt (&)
Cancer Prevention and Control Program,
Department of Oncology, Lombardi Comprehensive Cancer
Center, Georgetown University Medical Center, 3300
Whitehaven Street, Suite 4100, Washington, DC 20007, USA
e-mail: mandelbj@georgetown.edu
C. B. Schechter
Departments of Family & Social Medicine and Epidemiology
and Population Health, Albert Einstein College of Medicine,
Bronx, NY, USA
N. T. van Ravesteyn  E. A. M. Heijnsdijk  H. J. de Koning
Department of Public Health, Erasmus MC, Rotterdam,
The Netherlands
123
Breast Cancer Res Treat (2012) 136:823–835
DOI 10.1007/s10549-012-2274-3
Obesity exerts numerous, often opposing effects on the
chain of events leading to possible death from breast can-
cer. It increases breast cancer incidence in post-menopausal
women, but reduces risk in pre-menopausal women [9–13].
Obesity also leads to more favorable tumor types [13, 14],
greater sensitivity of detection [15], but more advanced
stage [16–18], lower treatment effectiveness [19, 20], and
greater competing mortality [8, 21, 22]. The Institute of
Medicine recently noted that simulation modeling is par-
ticularly useful for evaluating the net impact of a factor
such as obesity that affects multiple points in a disease
process differentially [23]. Modeling is also helpful in
evaluating the role obesity plays in racial disparities by
providing a ‘‘virtual laboratory’’ to evaluate the impact of
varying conditions that cannot be readily tested in the
population, such as the net impact of reductions in obesity
prevalence on breast cancer rates [24, 25].
In this article, we use two established, independent sim-
ulation models to evaluate how obesity affects breast cancer
incidence and mortality in US Black and White women. We
also investigate how much of the disparity in breast cancer
mortality is due to the differential prevalence of obesity. Our
results are intended to inform debates about effective strat-
egies to reduce racial gaps in breast cancer mortality and
reduce the burden of breast cancer for all women.
Methods
The two models, called MISCAN and SPECTRUM, were
developed within the Cancer Intervention and Surveillance
Modeling Network (CISNET) [26] and were exempt from
institutional review board approval. The models have been
described in detail elsewhere [2, 24, 27, 28]. Briefly, both
are discrete event-driven, continuous-time state transition
models that project US breast cancer population trends in
the absence of screening or treatment and then overlay
screening and adjuvant treatment diffusion over time.
Breast cancer is depicted as having a preclinical screen-
detectable period (sojourn time) and a clinical detection
point. On the basis of mammography sensitivity (or
thresholds of tumor size detection), screening identifies
disease in the preclinical screen-detectable period and
results in the identification of earlier stage or smaller, more
curable tumors than might occur via clinical detection,
resulting in reduced breast cancer mortality. Age at diag-
nosis, estrogen-receptor (ER) and human epidermal growth
factor-2 (HER2) status and tumor size- or stage-specific
treatment have independent effects on probability of a cure
(or survival). Women can die of breast cancer or of other
causes.
MISCAN portrays tumor growth, where tumors can be
detected once they are larger than a detection threshold and
cured if the diameter at detection is below a fatal threshold.
In SPECTRUM, tumors progress through stages, with
screening effects due to age- and stage-shifts and treatment
reducing the hazard of death. In both, ductal carcinoma
in situ (DCIS) can regress, remain and be diagnosed, or
progress to invasive cancer. In previous collaborations, the
models generated similar estimates of incidence and mor-
tality [2, 24, 29].
Model parameters
Using data from clinical trials and epidemiological studies,
the models employ a common set of parameters to portray
race-specific effects and then superimpose the impact of
obesity on each parameter (Table 1). Each includes model-
specific parameters to represent sojourn, lead, and dwell
time within stages or tumor diameter growth times and
stage distribution or tumor size [2, 24, 27, 28].
Demographic data and obesity
The population consists of cohorts of US Black and White
women born between 1890 and 2010 [30]. We start in 1890 to
project prevalent cancers in the 1970s. Women are assigned
to being obese or non-obese based on rates observed for
their age, birth cohort, race, and the calendar year using
prevalence data from the National Health and Nutrition
Examination Survey I (1970–1975), II (1976–1980), III
(1988–1994), and 1999–2004 [8]. These data are extrapo-
lated to 2009–2010 using the most recent NHANES data [7].
We do not allow transitions from obese to non-obese (or back
again to obese) because there are insufficient data on how
such transitions would affect all the model parameters.
Breast cancer incidence
Breast cancer incidence in the absence of screening is
based on an age-period-cohort (APC) model [31]. We
extrapolate forward based on rates in 2000 so do not cap-
ture the more recent decrease in incidence [32]. The APC
model is adapted for Black women using an age-specific
relative risk (RR) based on Black versus White incidence
[24]. Based on a synthesis of studies, obesity is modeled as
increasing breast cancer incidence in post-menopausal
women by a RR of 1.25 and decreasing rates in pre-
menopausal women by a RR of 0.60 [9–11, 33].
Mammography
The dissemination of mammography is depicted based on
the age of receipt of the first mammography and the
interval between subsequent mammograms using data
from the Breast Cancer Surveillance Consortium (BCSC)
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[34, 35]. This parameter was extended using BCSC data to
include different screening rates and intervals for Blacks
and Whites [36, 37]. Mammography use does not generally
vary by BMI (except for the extremes for underweight and
extremely obese) [38], so we assume obesity has no effect
on mammography dissemination.
Sensitivity and specificity of mammographic screening
for DCIS and invasive cancer were estimated by age group
(under and over 50), screening round (first or subsequent),
and obesity group using unpublished BCSC data [39].
There was no difference in test characteristics by race.
Stage distribution
The tumor stage distribution in the absence of screening for
Black and White women was estimated from the SEER
Table 1 Common model input parameters
Parameter Race-specific Source Obesity-specific Source
Births Birth cohorts born from 1890 to 2000 by race [30] –
Obesity prevalence Race, cohort and year-specific [74, 75] – [74, 75]
Incidence Age-period cohort model with age-specific
relative risk of Black versus White incidence
[24, 31] For obese (BMI C 30) vs. non-obese:
\50: RR 0.6 (95 % CI 0.4–1.0)
50?: RR 1.25 (95 % CI 1.1–2.0)
Assume obesity effect equal by race
[9–11, 33]
Mammography use Dissemination based on age- and race-specific
rates for first and subsequent exams and
intervals between screenings.





Age-specific rates for first and subsequent





Sojourn time 2 years if age B40
2 ? 0.2(age - 40) if age 40–49
4 if age C50
Assume equal by race
[76] Assume sojourn time is equal across
BMI categories.
–
ER/HER2 Regression model using NCCN data
from 2,646 women
[24] Risk of ER? breast cancer, obese vs.
non-obese:
\50: RR 0.86 (95 % CI 0.77–0.95)
50?: RR 1.78 (95 % CI 1.50–2.11)
Assume no effect HER2
[14]
Mean stage dwell time DCIS 5 years
Stage 1 2.60 years
Stage 2a 1.26 years
Stage 2b 1.27 years
Stage 3 4.08 years
Stage 4 N/A
Assume equal by race
[27, 28] Assume no effect of obesity –
Stage distribution





Screened Varies by age and race
Survival without Rx Survival by race from SEER in 1975–1979 [40] Assume no effect of obesity on breast
cancer-specific survival
–
Treatment dissemination Blacks 22 % less likely to receive chemo;
10 % (\age 50) to 15 % (age 50?) less
likely to get hormonal Rx than Whites
[43, 44] Obesity has no effect on treatment
dissemination
[52]
Treatment effectiveness Meta-analyses of randomized trial results;
assume treatment effectiveness is equal by
race
[47–51] Reduce hazard ratios by 0.55 for obese
ER-negative women who receive dose
reductions; 30 % of obese women have
a dose-reduction
[19, 20]
Other cause mortality Age-, race-, and cohort-specific all-cause
mortality rates by year
[54, 55] NHANES-linked mortality database [8]
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data in 1975–1979 before widespread use of mammogra-
phy [40] and updated over time using race-specific BCSC
data for unscreened (clinically detected) women. Stage
distributions among screened women were estimated using
race-specific BCSC data from 1996 to 2007 by screening
intervals and first versus subsequent screen detection
(unpublished data).
Obesity is associated with more advanced tumors at
diagnosis overall [16, 41] and in Blacks and Whites [17,
18], even after accounting for mammography use [15].
Therefore, we used BCSC data stratified by BMI and age
group to represent the impact of obesity on stage for
unscreened and screened women of both races.
Tumor biomarkers
We estimated the joint distribution of ER and HER2 status
by age, year, stage, and race using data from 1997 to 2005
[24, 42]. As obesity affects the rate of ER? tumors differ-
entially by menopausal status [14], we applied RRs of 0.86
and 1.78 to the probability of having ER? cancer among
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Fig. 1 Model predicted age-
adjusted breast cancer incidence
and mortality by model, race
and calendar year versus
observed SEER rates for US
women age 25?
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obesity had no direct impact on ER- tumors. There were
insufficient data on obesity and HER2, so we assumed that
obesity had no impact on HER2 distribution.
Treatment
Age-, year-, AJCC stage (or tumor size), and ER/HER2-
specific use of adjuvant hormonal and chemotherapy as
disseminated from 1975 to 2000 was estimated from NCI’s
Patterns of Care studies [43, 44] and updated through 2010
using unpublished data from the National Comprehensive
Cancer Network (NCCN) Outcomes Database. Compared
to White women, Black women were 22 % less likely to
receive multi-agent chemotherapy and 10 % (age \50) to
15 % (age 50?) less likely to receive hormonal therapy.
These Black–White differences were applied to the treat-
ment dissemination curves. Obese and non-obese women
had similar treatment patterns and obesity did not modify
treatment in Blacks [45].
Women with ER? invasive tumors receive hormonal
treatment (tamoxifen from 1980 to 1999; tamoxifen if
\50 years and anastrozole if C50 years from 2000 to
present) and non-hormonal treatment (CMF or anthracy-
cline-based regimen from 1975 to 1999; anthracycline-
based plus taxanes from 2000 to present). Women with
ER- invasive tumors receive non-hormonal therapy only.
Women with DCIS and ER? tumors receive hormonal
therapy. Women with HER2? tumors received trast-
uzumab beginning in 2005 [46].
Treatment effectiveness is based on RCTs [47–50].
Hormonal and chemotherapy regimens are equally effec-
tive in Black and White women [51]. We adjusted survival
to reflect the fact that *30 % of obese patients experience
dose reductions and that ER- cases having dose-reductions
experience decrements in survival of 55 % [52, 53].
Fig. 2 Model predicted age-adjusted breast cancer stage distributions
and tumor sizes by model and race versus observed SEER rates in
2007–2009 for US women age 25?
Table 2 Projected breast cancer incidence in 2012 among women 25? by race, obesity, and model
White Black
Obese Non-obese All (weighted
sum of obese ?
non-obese)
Obese Non-obese All (weighted
sum of obese ?
non-obese)
SPECTRUM model
Age-adjusted incidence rate per 100,000a 300.3 267.4 277.4 247.6 223.7 229.8
# of casesb 91,688 175,643 267,331 11,619 17,461 29,080
Proportion of cases in the US population
attributable to obesityc
4.5 % 3.6 %
MISCAN model
Age-adjusted incidence rate per 100,000a 290.7 258.2 267.5 252.7 223.0 229.7
# of casesb 88,989 172,768 261,757 11,463 17,717 29,180
Proportion of cases in the US population
attributable to obesityc
3.9 % 2.5 %
a For comparability the model outputs for both race groups are age adjusted using the standard US million-population
b The number of cases is calculated from the model projected age- and race-specific rates, the age- and race-specific population distribution
projected for 2010, and the age- and race-specific prevalence of obesity
c The attributable fraction of cases in the overall US population that are due to obesity is estimated by the prevalence of obesity * (incidence in
obese - incidence in non-obese)/(prevalence of obesity * incidence in obese ? (1 - prevalence of obesity) * incidence in non-obese)
Breast Cancer Res Treat (2012) 136:823–835 827
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No adjustment was applied for ER? patients. We assumed
that the impact of dose reductions was the same across all
race groups and that obesity had no effects on treatment
effectiveness of hormonal or trastuzumab therapy [9].
Mortality
SEER data from 1975 to 1979 were used to estimate breast
cancer survival before screening and adjuvant treatment
was available. Age-, race- and cohort-specific non-breast
cancer mortality were calculated by subtracting breast
cancer from all-cause mortality [54, 55]. The impact of
obesity on non-breast cancer mortality was derived from
NHANES-mortality linked data [8].
Analysis
The models simulate 1975–2020 age-adjusted breast can-
cer incidence and mortality rates for Black and White
obese and non-obese women; adjustment is based on the
standard US million population. This common referent
population allows comparisons of results, as the age dis-
tributions of the population differ by race and obesity
status. Overall, the US rates were estimated using a prev-
alence-weighted sum of the age-adjusted rates for the obese
and non-obese women. Age-specific rates by race are used
with the projected 2010 age-specific distribution of the
respective populations [56] weighted by obesity prevalence
to calculate numbers of cases and deaths. Additionally, we
calculate the fraction of cases and deaths attributable to
obesity. Finally, we investigate the effect of obesity on the
difference in mortality between White and Black women,
after considering the effect of race-differences in demog-
raphy, incidence, natural history, screening use alone,
adjuvant treatment use alone, and both screening and
treatment. To this end, we sequentially substitute parameter
values relating to these factors in the White version of the
models with corresponding values from the Black version.
In the final step, we add the prevalence of obesity among
Blacks to the models. At each step, we compute the frac-
tion of the mortality difference between White and Black
women explained by each factor. The predicted breast
cancer mortality rates at each step are also compared to the
3-year average of observed rates for Black women [3].
Model validation
The model validation has been described in previous
publications [27, 28]. Results from two models provide
implicit cross-validation, a range of plausible impacts of
obesity, and a measure of uncertainty. Internal reliability
was evaluated by combining incidence and mortality rates
for obese and non-obese women in proportion to their age-
and race-specific prevalence of obesity to verify that we
reproduced overall population rates. Reliability of the
model adaptations for obesity was also evaluated by
comparing model outputs to observed SEER data.
Results
Observed incidence trends were accurately reproduced by
both models. Mortality rates are reproduced for White
women, and the shape of the curve is similar for Blacks,
but lower than SEER (Fig. 1). The models mirror observed
data showing that stage distribution (or tumor size) is more
favorable in White than in Black women, but the models
predict a slightly more favorable distribution for Blacks
than actually observed (Fig. 2).
Impact of obesity on incidence
Obesity increases the incidence of breast cancer for both
races, and the fraction of cases attributable to obesity is
similar for Whites (3.9–4.5 %, across models) and Blacks
(2.5–3.6 %) (Table 2; Fig. 3). The net impact of obesity on
incidence is the result of opposing risk by age. The pre-
dicted incidence in obese women \50 years is 37–47/
100,000 for Whites and 32–44/100,000 for Blacks. Among
non-obese White and Black women \50 years, the corre-
sponding rates are 47–60/100,000 and 43–60/100,000,
respectively. Thus, elimination of obesity would actually
increase the number of cases among women\50 years. For
women aged 50?, obesity accounts for 5.5–6.4 % and
5.3–8.1 % of cases for White and Black women, respec-
tively (data not shown).
Impact of obesity on breast cancer mortality
Obesity increases mortality rates for both race groups and
accounts for 4.4–9.2 % and 3.1–8.4 % of the total deaths
for Whites and Blacks, respectively, across models
(Table 3; Fig. 4). This translates into 1,400–3,552 deaths in
Whites and 148–412 deaths in Blacks that could be avoided
each year if obesity were eliminated. Among women
\50 years, obesity decreases death rates given the large
decrease in incidence associated with its protective effects.
For women age 50? of both race groups, obesity accounts
for about 5.1–11.5 % of the deaths in the overall US
population.
Obesity and impact on Black–White differences in rates
The observed age-adjusted mortality rate was 33.9/100,000
in Whites and 48.1/100,000 in Blacks from 2007 to 2009
828 Breast Cancer Res Treat (2012) 136:823–835
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(latest years available). In Table 4, these values are com-
pared to model predictions based on sequential replace-
ment of parameter values in the White model by those from
the Black model to test how much the higher prevalence of
obesity in Black compared to White women affects the
differences in mortality. As can be seen in Step 6, there is
no net effect of race differences in obesity prevalence on
mortality disparities. This result occurs because the higher
prevalence of obesity among Black versus White women
\50 years decreases cases and mortality, but increases
these outcomes from ages 50 to 74. As White women
have a higher prevalence of obesity than Blacks after age
74, substituting the Black obesity prevalence (vs. White)
decreases cases and deaths among the oldest women. Thus,
differences in obesity prevalence do not account for the net
age-adjusted mortality disparities between Blacks and
Whites.
Discussion
This is the first study to use collaborative modeling to
evaluate the impact of obesity on breast cancer incidence
and mortality in White and Black women and to assess
whether differences in obesity prevalence account for race
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Fig. 3 Model predicted age-
adjusted breast cancer incidence
rates over time by model, race
and obesity for US women
age 25?
Breast Cancer Res Treat (2012) 136:823–835 829
123
about 3–4 % of the cases and 3–9 % of the deaths in both
the race groups. Variations in obesity prevalence have no
net effect on the mortality differences between Blacks and
Whites.
The overall modest impact of obesity represents the
balance of an increase in cases/deaths among a large
number of post-menopausal women and a decrease among
a smaller number of pre-menopausal women. The obesity
attributable fraction of 5.3–8.1 % of cases among White
and Black women 50 years and older we observed is
similar to, but lower than prior US (8.9 %) [15] and UK
estimates (8.7 %) because those included both overweight
and obese women [57]. If obesity were eliminated we could
avoid more than 12,000 cases among White women and
1,000 in Black women. There are few measures that can
prevent so many breast cancer cases, except perhaps
Tamoxifen use by high-risk women [58].
Obesity accounts for \10 % of breast cancer deaths
across race groups. For colorectal cancer, elimination of
obesity and other risk factors could reduce mortality by up
to 16 % [59]. Decreasing obesity has other important effects
on health, such as reductions in risk of other cancers and
heart disease, and could lower health care costs [21, 22, 60],
making it an important public health target. However, while
we can easily eliminate obesity in our model ‘‘laboratory,’’
it is very difficult to treat in actual practice [61, 62]. Thus,
the modest impact projected by our models may not be
achievable, but provides an upper estimate of the impact of
obesity control efforts on breast cancer.
The conclusions of both models were very similar, but
MISCAN uses a cure model that generates lower breast
cancer mortality rates than SPECTRUM that applies a
hazard of breast cancer death over time [24, 27, 28]. MI-
SCAN also projects less mortality difference between
obese and non-obese women due to use of continuous
tumor size rather than discrete tumor stages, yielding lower
obesity attributable mortality fractions. These differences
capture some uncertainty and provide users with a range of
plausible results.
Obesity is a modest but potentially meaningful target in
reducing the burden of breast cancer, but it does not appear
to account for net racial differences in age-adjusted mor-
tality. This conclusion is consistent with the recent finding
of Lu et al. [63] that obesity did not affect breast cancer
survival in Blacks ages 35–64, although it had a modest
impact for Whites. Unfortunately, that study did not have
information on treatment. Others have found that adjusting
for obesity does not remove Black–White differences in
deaths from breast cancer [64, 65].
Our approach builds on and extends prior modeling of the
impact of obesity on cancer outcomes [59] by incorporating
the impact of obesity on incidence, screening, and treatment
parameters and examining results separately by race. Despite
the strengths of our approach, there are some caveats that
should be considered in evaluating the results. First, although
weight can change over the life course [25], we modeled
obesity as constant after onset given the unavailability of
data to link changes in weight to the multiple input param-
eters. This may underestimate the impact of obesity because
a transition from non-obese to obese around menopause,
which is a common pattern, maximizes risk during both
periods. Next, as in other models we consider two categories
Table 3 Projected breast cancer mortality in 2012 among women 25? by race, obesity, and model
White Black
Obese Non-obese All (weighted
sum of obese ?
non-obese)
Obese Non-obese All (weighted
sum of obese ?
non-obese)
SPECTRUM model
Age-adjusted mortality rate per 100,000a 44.8 33.4 36.6 47.8 36.3 39.2
# of deaths from breast cancerb 14,363 24,398 38,761 2,059 2,872 4,931
Proportion of deaths in the US population
attributable to obesityc
9.2 % 8.4 %
MISCAN Model
Age-adjusted mortality rate per 100,000a 35.8 30.9 32.2 41.1 36.0 37.3
# of deaths from breast cancerb 10,780 21,052 31,832 1,846 2,863 4,709
Proportion of deaths in the US population
attributable to obesityc
4.4 % 3.1 %
a For comparability the model outputs for both race groups are age adjusted using the standard US million-population
b The number of deaths was calculated from the model projected age- and race-specific rates, the age- and race-specific population distribution
projected for 2010, and the age and race-specific prevalence of obesity
c The attributable fraction of deaths in the overall US population that are due to obesity is estimated by prevalence of obesity * (mortality in
obese - mortality in non-obese)/(prevalence of obesity * mortality in obese ? (1 - prevalence of obesity) * mortality in non-obese)
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of obesity [59] but do not consider an overweight category or
body fat distribution, given the paucity of consistent epide-
miological data across parameters for a wider range of
characterizations. Others have not found a difference in
estimates of risk [66] or survival [67] based on different
categorizations of weight and there is no consistent evidence
to suggest that level of obesity interacts with race in its
effects on cancer incidence [66]. Obesity is also the net result
of diet and physical activity, and these factors may affect
survival [68, 69]. However, it remains difficult to separately
estimate the impact of these components (or their molecular
correlates) [70–73] on the prevention, screening, treatment,
and survival parameters included in the models. This is an
important area for future research [25]. Until then, our results are
useful as obesity is the most robustly related to breast cancer
outcomes among measures of energy balance [66, 67].
Overall, these results represent the first comprehensive
examination using comparative modeling of obesity and
how it affects the entire breast cancer process from risk of
disease to the type of disease at presentation and treatment
impact in the context of competing mortality. The results
indicate that obesity exerts a modest impact on breast
cancer and does not explain net race disparities in outcome.
However, obesity remains one of the few known modifi-
able risk factors for this and other diseases, increasing its
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Fig. 4 Model projected age-
adjusted breast cancer mortality
rates over time by model, race
and obesity in US women
age 25?
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